Release of Restricted Securities
Released
Released
Announcement PDF
ASX Announcement
21 November 2025
JOIN MICROBA’S INTERACTIVE INVESTOR HUB
For more Company information and to engage with management by asking questions about Microba’s latest announcements
and updates, visit ir.microba.com/welcome
Microba Life Sciences Ltd | ABN 82 617 096 652 | L10, 324 Queen Street, Brisbane QLD 4000 Australia | 1300 974 621
Release of Restricted Securities
Microba Life Sciences Limited (ASX: MAP) (“Microba” or the “Company”), advises in accordance with ASX
Listing Rule 3.10A, that the following securities, which were subject to voluntary escrow as part of the Company’s
acquisition of Invivo Clinical Limited in December 2023 will be released from escrow as follows:
• 13,141,578 fully paid ordinary shares will be released from escrow on 6 December 2025.
The release of these securities does not affect the Company’s total issued capital.
This announcement has been authorised for release by the Chair and CEO.
For further information, please contact:
Dr Luke Reid
Chief Executive Officer
luke.reid@microba.com
Investor / Media Relations
investor@microba.com
https://ir.microba.com/welcome
About Microba Life Sciences Limited
Microba is at the forefront of microbiome health and human care. With world-leading science, insights and
collaboration tools, Microba's vision is to deliver clinical-grade microbiome tests that helps people live healthier,
happier lives. Better science. Better insights. Better health. Microba - Expect better. www.microba.com
Share your feedback
Discover